
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
over 26 years ago
Ischemic Stroke: Acute Management and Secondary Preventionover 26 years ago
Is Cost-Effectiveness Modeling Useful?




